Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

Key Points

Key points are not available for this paper at this time.

Abstract

Our results indicate that biologically targeted degradation of FOXM1 is an attractive therapeutic strategy, and antagonist peptide-containing FOXM1-PROTACs as both degrader and inhibitor of FOXM1 could be developed as a safe and promising drug for FOXM1-overexpressed cancer therapy.

Bookmark

View Full Paper

Cite This Study

Wang et al. (Wed,) studied this question.

synapsesocial.com/papers/69db5603f7e0c66ced8359f5 https://doi.org/https://doi.org/10.1186/s13046-022-02483-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cell-Penetrating Peptides: Design, Synthesis, and Applications2014 · 943 citations
2Over‐expression of FoxM1 stimulates cyclin B1 expression2001 · 183 citations
3Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L12021 · 504 citations
4A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells2011 · 550 citations
5FOXM1 Promotes Lung Adenocarcinoma Invasion and Metastasis by Upregulating SNAIL2015 · 78 citations

Bookmark

View Full Paper